Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

BACKGROUND: Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS programs. We report the 1-year efficacy and safety in patients with AS and an inadequate response to biologic disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraliakos, Xenofon, van der Heijde, Désirée, Sieper, Joachim, Inman, Robert D., Kameda, Hideto, Li, Yihan, Bu, Xianwei, Shmagel, Anna, Wung, Peter, Song, In-Ho, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506267/
https://www.ncbi.nlm.nih.gov/pubmed/37723577
http://dx.doi.org/10.1186/s13075-023-03128-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506267/
https://www.ncbi.nlm.nih.gov/pubmed/37723577
http://dx.doi.org/10.1186/s13075-023-03128-1

Ejemplares similares